hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06283004 id: 2024-1/30 briefTitle: Investigation of Walking Training With Different Slope Types in COPD Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-06-01 date: 2026-06-01 date: 2024-02-28 date: 2024-02-28 name: Acibadem University class: OTHER name: Bezmialem Vakif University briefSummary: Chronic obstructive pulmonary disease (COPD) is a disease that continues to generate a great deal of research and this research must continue, both because it is not completely curable and because of the large patient population. The importance and benefits of exercise training in COPD patients are clear. One of the most preferred types of exercise training is the so-called aerobic exercise training, which typically takes the form of walking. A typical walking training does not use a slope or may include an uphill slope. However, recently there have been publications about downhill walking and its benefits in COPD. Walking on a level, uphill, and downhill slope may have the potential to result in different gains by using different muscle groups more. Therefore, this study aimed to compare the effects of walking training on exercise capacity, respiratory functions, muscle strength, and functional status in COPD patients with three different slope types: level, uphill, and downhill. conditions: Pulmonary Disease, Chronic Obstructive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 51 type: ESTIMATED name: Downhill walking training name: Level walking training name: Uphill walking training measure: 6 Minutes Walking Distance (6MWD) measure: Spirometric measurements (Forced vital capacity) measure: Spirometric measurements (First second forced expiratory volume) measure: Spirometric measurements (FEV1/FVC ratio) measure: Spirometric measurements (Peak Expiratory Flow) measure: Spirometric measurements (Maximum Intermediate Expiratory Flow) measure: Muscle strength measurements (skeletal muscles) measure: Muscle strength measurements (respiratory muscles) measure: 30-second sit and stand test measure: Functional performance inventory measure: Dyspnea measure: Fatigue measure: Level of exertion sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282991 id: B7461028 briefTitle: A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled overallStatus: COMPLETED date: 2020-07-22 date: 2021-01-18 date: 2021-01-18 date: 2024-02-28 date: 2024-02-28 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled.
All participants in this study had received lorlatinib. Lorlatinib is a tablet that is taken by mouth at home. They continued to take dacomitinib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective. conditions: Non-Small Cell Lung Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 73 type: ACTUAL name: Lorlatinib measure: The treatment pattern from initial diagnosis to current lorlatinib treatment. measure: objective response rate (ORR) measure: overall survival measure: progression-free survival measure: 1-year OS rate measure: time-to-treatment failure for all NSCLC measure: time-to-treatment failure of lorlatinib measure: The clinical nature, incidence, duration, and severity of lorlatinib-related safety profile sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch city: Kaohsiung City zip: 83301 country: Taiwan lat: 22.61626 lon: 120.31333 facility: Chung Shan Medical University Hospital city: Taichung zip: 402 country: Taiwan lat: 24.1469 lon: 120.6839 facility: Taichung Veterans General Hospital city: Taichung zip: 407219 country: Taiwan lat: 24.1469 lon: 120.6839 facility: National Taiwan University Hospital city: Taipei zip: 100 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Taipei Veterans General Hospital city: Taipei zip: 11217 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Chang Gung Memorial Hospital - Linkou Branch city: Taoyuan City zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06282978 id: GEM-RANTAB id: 2023-504273-21 type: EUDRACT_NUMBER briefTitle: Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes overallStatus: RECRUITING date: 2023-11-23 date: 2025-05 date: 2029-12 date: 2024-02-28 date: 2024-03-06 name: PETHEMA Foundation class: OTHER briefSummary: The goal of this phase II, open-label, single-arm, multicenter study is to evaluate i) the efficacy and ii) safety of elranatamab monotherapy at the dose of 76 mg subcutaneously in participants with RRMM after at least one or two prior lines of therapy who have received prior treatment with immunomodulatory drugs, protease inhibitors, and anti-CD38 therapy and were refractory to the last line of therapy, defined as progression while receiving treatment or in the first 60 days after the last dose of treatment.
nctId: NCT06282965 id: AngT-001 briefTitle: Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury acronym: ANGel T overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-09 date: 2027-09 date: 2024-02-28 date: 2024-02-28 name: University of Arizona class: OTHER name: United States Department of Defense briefSummary: The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI).
Researchers will compare three groups: two groups that receive different doses of Angiotensin (1-7) and one group that receives a look-alike treatment with no active drug. This will allow researchers to see if the drug has any negative effects and whether it improves mental functioning and physical signs of brain damage after a TBI. conditions: Traumatic Brain Injury studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Investigators, study site staff, participants, and caregivers will be unaware of the participant treatment assignments for the duration of the study. The pharmacist will prepare the study treatment and will be unmasked. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 90 type: ESTIMATED name: Angiotensin (1-7) name: Sterile saline measure: Number of participants with adverse events measure: Performance on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) measure: Cognitive functions after Angiotensin (1-7) treatment as measured by the Montreal Cognitive Assessment (MoCA) measure: Function after Angiotensin (1-7) treatment, as measured by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) measure: Effects of Angiotensin (1-7) on acute CNS damage biomarker phosphorylated tau (p-tau) measure: Effects of Angiotensin (1-7) on CNS damage biomarker phosphorylated tau (p-tau) after 90 days measure: Effects of Angiotensin (1-7) on brain white matter integrity measure: Effects of Angiotensin (1-7) on length of hospital stay measure: Incidence and duration of delirium as assessed by the Confusion Assessment Method (CAM) measure: Change in suicidal ideation and behavior as assessed by the Patient Health Questionnaire (PHQ-9) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282952 id: 198/2023 briefTitle: NEwborn Infant of a Mother With Obesity - Fecal Microbiome Transplantation, RCT acronym: NEMO-FMT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-31 date: 2028-12-31 date: 2024-02-28 date: 2024-02-28 name: Oulu University Hospital class: OTHER name: University of Oulu name: University of Turku name: Turku University Hospital name: University of Helsinki name: Academy of Finland name: Biocenter Oulu briefSummary: The goal of this clinical trial is to investigate the differences in microbiota, height and weight between infants born by cesarean section to obese mothers and randomized to receive fecal microbiota transplant after birth. The main questions it aims to answer are:
* Is the source of colonization a modifiable factor and can it be changed by using an early fecal microbiota transplant. conditions: Fecal Microbiota Transplantation conditions: Cesarean Section conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The eligible women are randomized into two groups in which their newborns receive either fecal microbiota transplant from 1) their own mother (50 newborns) or 2) the Microbiome Biobank (50 newborns). The randomization 1:1 is done in blocks of 4 mothers. The study is double blinded. If mother has Group B streptococcus colonization or other infectious disease described in table 1, and microbiota transplant cannot be given or if mother will have non-elective-CS and the microbiome transplant is not available, the mother is included in 3) the observational cohort, which is "open" (not blinded). primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: The research statistician performs the computer-generated randomization. The study nurse prepares the fecal transplant according to the randomization. Study participants or investigators are not aware of study group. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 150 type: ESTIMATED name: Fecal transplant measure: Microbial composition profiles in fecal sample measure: Height in centimeters measure: Height z-score measure: Weight in kilograms measure: Weight-for-length (%) measure: The source of colonization by exclusively shared genes (ESGs) sex: FEMALE minimumAge: 18 Years maximumAge: 49 Years stdAges: ADULT hasResults: False
nctId: NCT06282939 id: 20234314 briefTitle: Optima Coil Performance in The Interventional Management of Intracranial Aneurysms Registry acronym: OPTIMA overallStatus: RECRUITING date: 2023-11-01 date: 2026-12-01 date: 2027-12-01 date: 2024-02-28 date: 2024-02-28 name: HCA Healthcare Research Institute class: OTHER name: Balt USA briefSummary: This is a prospective, open-label, consecutive enrollment, multi-center, U.S. registry of patients with intracranial aneurysms who are treated with the Optima Coil System.
The primary objective of this registry is to evaluate the safety and effectiveness of the OptimaTM Coil System, including the OptiMAX Coils, in the real-world treatment of intracranial aneurysms. Imaging will be analyzed by a designated core neuroimaging lab to assess procedural success and aneurysm occlusion rates. Intent to treat population total: 700 patients 600 patients, up to 100 screen failures. conditions: Intracranial Aneurysm studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: OPTIMA and OPTIMAX Coils manufactured by Balt USA measure: Measure Adequate Occlusion Using modified Raymond-Roy Occlusion Class (MRRC) I and II score measure: Assess coiling alone or in combination with adjunctive devices for approximately 400 patients measure: Evaluate Coiling with flow diversion for approximately 200 subjects measure: Subgroup analyses will be performed examining: measure: Analyze outcomes of small aneurysms defined as smaller than 5mm measure: Adequate occlusion measure: Packing density measure: Complete occlusion measure: Complete occlusion measure: Recanalization rate measure: Retreatment rate measure: Change in degree of disability measure: The number of coils used in an aneurysm measure: Procedural fluoroscopic time measure: Primary Safety Endpoint measure: Secondary Safety Endpoint sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Med City Plano status: RECRUITING city: Plano state: Texas zip: 75075 country: United States name: Albert Yoo role: CONTACT phone: 972-566-5411 email: ajyoo74@gmail.com name: Pauline Matheri role: CONTACT phone: 615-329-7274 email: Pauline.Matheri@HCAhealthcare.com lat: 33.01984 lon: -96.69889 hasResults: False
nctId: NCT06282926 id: 324811 briefTitle: Role of 3D Echocardiography Knowledge-based Reconstruction in ACHD overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-06 date: 2025-09 date: 2024-02-28 date: 2024-02-28 name: Guy's and St Thomas' NHS Foundation Trust class: OTHER name: Manchester Metropolitan University briefSummary: The main objective of this study is to evaluate the reproducibility and accuracy of TTE-3DKBR in assessing RV volume and EF compared to the reference method of CMR in a group of ACHD patients with known moderate or severe PR after ToF repair.
As part of the validation study, the reproducibility of the TTE-3DKBR in assessing RV volume and EF will also be tested in a group of healthy adult volunteers. Additionally, TTE-3DKBR evaluation will be compared in both groups to the conventional 2D echocardiography measurements used in routine clinical practice, such as tricuspid annular plane systolic excursion (TAPSE), tissue Doppler imaging (TDI), fractional area change (FAC), and global longitudinal strain (GLS).
The study will end when the required number of patients have been enrolled and when the last subject undergoes the research dataset acquisition. The study may be terminated prematurely if it becomes apparent that the recruitment target cannot be met within the projected recruitment phase. conditions: Tetralogy of Fallot studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 72 type: ESTIMATED name: Echocardiography assessment measure: Evaluate the reproducibility and accuracy of TTE-3DKBR in assessing RV volume and EF compared to the reference method of CMR in a group of ACHD patients with known moderate or severe PR after ToF repair. measure: Evaluate the effects of chronic RV volume overload in this population within one-year follow-up using TTE-3DKBR and compare it with the conventional non-geometric echocardiography measurement of GLS. measure: Compare TTE-3DKBR evaluation to the conventional 2D echocardiography measurements used in routine clinical practice (TAPSE, TDI, FAC, and GLS). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282913 id: ---Oncology-Nursing-2024--- briefTitle: The Effect of Mindfulness Meditation overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-11 date: 2025-12 date: 2024-02-28 date: 2024-02-28 name: Gulhane Training and Research Hospital class: OTHER_GOV briefSummary: Cancer is a disease that causes the most deaths worldwide and is challenging for patients and caregivers both physically and psychosocially. Physicians and nurses working in oncology clinics perform a demanding profession providing compassionate care and treatment to patients struggling with life-threatening diseases. The emotional cost of caring for patients diagnosed with cancer can lead to compassion fatigue, burnout, and decreased psychological well-being among healthcare professionals. For this reason, this research is planned as a randomized controlled study to examine the effect of Mindfulness meditation practice on compassion fatigue, burnout, and psychological well-being in physicians and nurses working in oncology units. conditions: Burnout conditions: Compassion Fatigue conditions: Psychological Well-Being studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 64 type: ESTIMATED name: Mindfulness Meditation measure: compassion fatigue measure: burnout measure: psychological well-being measure: compassion fatigue measure: burnout measure: psychological well-being sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282900 id: 2024-1/15 briefTitle: Pain and Screen Addiction in University Students overallStatus: RECRUITING date: 2024-03-04 date: 2024-05 date: 2024-06 date: 2024-02-28 date: 2024-03-08 name: Acibadem University class: OTHER briefSummary: One of the most important factors why young people spend inactive time is the time they spend in front of the screen. Sedentary screen time refers to time spent using a screen-based device, such as a computer, television, smartphone, or tablet while being sedentary in any environment. The last decade has seen a disturbing increase in the amount of time young people spend in front of screens. Research shows that musculoskeletal disorders in the hand, wrist, arm, and neck occur at a high rate due to long-term and repetitive use of the smartphone, one of the electronic devices. People with musculoskeletal pain often complain of more than one area of pain.
The primary purpose of this study is to investigate the relationship between university students' use of various screen-based devices, the time they spend in front of the screen, and the number of painful areas they report on the body. Our secondary aim is to evaluate the relationship between pain, and screen time, and physical activity level. conditions: Student studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: University students measure: Investigating the use of screen-based devices measure: Musculoskeletal system evaluation measure: Physical activity assessment sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Acibadem University status: RECRUITING city: Istanbul state: None Selected zip: 34752 country: Turkey name: Elif E Safran, asst. prof. role: CONTACT phone: 500 4047 phoneExt: 216 email: elif.bayraktar@acibadem.edu.tr lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06282887 id: 2021-IIT-002 briefTitle: Effects of Music Therapy on Psychological States Among Cancer Patients Undergoing MRI Scans and A Relevant Mediator overallStatus: RECRUITING date: 2021-11-09 date: 2024-11-10 date: 2024-11-10 date: 2024-02-28 date: 2024-02-28 name: Guangzhou Concord Cancer Center class: OTHER briefSummary: The primary objective of this study is to examine the effects of a music therapy protocol on improving anxiety, symptom distress, and relaxation among cancer patients who are going through MRI scanning. Physiological data, such as pulse rates and respiration rates will be collected. Furthermore, data about scanning efficiency will be collected to assess if scanning efficiency is affected by the protocol implementation. The secondary study objective is to assess whether or not there is a relationship between patient attention to music during the intervention process and the changes in anxiety, symptom distress, and relaxation. conditions: Psycho-Oncology studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: All participants will be wearing a headphone, and they will not know if there will be music until they experience and finish the scan process.
Radiographers are blinding to avoid biases. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 80 type: ESTIMATED name: Music therapy measure: Anxiety measure: Symptom distress measure: Relaxation measure: Pulse rates measure: Respiration rate measure: Scanning efficiency measure: Patient satisfaction level measure: Patient attention to music (only for the music therapy group) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: GuangZhou Concord Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510700 country: China name: Juan Nie, Masters role: CONTACT lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06282874 id: CTONG2303 briefTitle: Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-07-01 date: 2027-03-01 date: 2024-02-28 date: 2024-02-28 name: Guangdong Association of Clinical Trials class: OTHER briefSummary: This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases. conditions: Carcinoma, Non-Small-Cell Lung conditions: Brain Metastases conditions: Leptomeningeal Metastasis studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Lorlatinib measure: intracranial objective response rate（iORR） measure: Progression-free survival (PFS) and intracranial PFS（iPFS） measure: Obiective response rate (ORR) measure: Disease control rate (DCR) and intracranial disease control rate (iDCR) measure: Overall survival measure: Number of participants with adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guangdong Provincial Perople's Hospital city: Guangzhou state: Other (Non U.s.) zip: 510080 country: China name: Chang Lu role: CONTACT phone: 02083827812 email: luchang@gdpg.org.cn name: Jin-Ji Yang role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06282861 id: ANTES B+ id: 2023-507304-32 type: EUDRACT_NUMBER briefTitle: ANTES B+ Clinical Trial acronym: ANTES B+ overallStatus: RECRUITING date: 2024-02-29 date: 2025-09 date: 2025-09 date: 2024-02-28 date: 2024-03-05 name: Fundacio Privada Mon Clinic Barcelona class: OTHER name: GlaxoSmithKline briefSummary: Current guidelines recommend initial treatment with dual long-acting bronchodilator therapy (LABA-LAMA) in patients with Chronic Obstructive Pulmonary Disease (COPD) of group B (defined by CAT≥10 and none or 1 moderate exacerbation). However, the investigators hypothesize that there is a subgroup of B patients (B+) at a particularly high risk for poor clinical control, characterized by the following:
1028 patients will be randomly allocated to receive either the standard therapy or Trelegy and will be monitored by the investigators for 1 year in 2 on-site visits + 2 remote visits. conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase IV, open-label, prospective, pragmatic, interventional, randomized (1:1), multicenter, controlled, 12-month follow-up trial. primaryPurpose: PREVENTION masking: NONE count: 1028 type: ESTIMATED name: Trelegy Ellipta 100/62.5/25Mcg Inh 30D name: Brimica name: Duaklir name: Ultibro name: Ulunar name: Xoterna name: Anoro name: Laventair name: Spiolto Respimat name: Yanimo name: Foradil name: Broncoral name: Formoterol stada name: Oxis name: Formatris name: Formoterol Aldo name: Onbrez name: Oslif name: Hirobriz name: Striverdi name: Beglan name: Betamican name: Inaspir name: Serevent name: Soltel name: Eklira name: Bretaris name: Seebri name: Tovanor name: Enurev name: Spiriva name: Tavulus name: Sirkava name: Braltus name: Gregal name: Incruse name: Rolufta measure: Clinical Control (CC) measure: Clinical Important Deterioration (CID) measure: Patients persistently controlled measure: Time to deterioration measure: Time to no control event of CC - Stability Domain measure: Time to no control event of CC - Impact Domain measure: Time to deterioration event of CID-CAT Exacerbations measure: Time to deterioration event of CID-CAT Spirometry measure: Exacerbation rate measure: Time to first Exacerbation measure: Spirometry changes measure: Independent predictors sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Clínic Barcelona status: RECRUITING city: Barcelona state: Catalunya zip: 08036 country: Spain name: Àlvar Agustí role: CONTACT phone: 93 227 57 79 email: aagusti@clinic.cat name: Nestor Soler role: CONTACT lat: 41.38879 lon: 2.15899 hasResults: False